Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer (MACRO)

• ClinicalTrials.gov Identifier: NCT02012634
• Recruitment Status: Unknown
• First Posted: December 16, 2013
• Last Update Posted: November 13, 2014
• Sponsor: Xijing Hospital
• Collaborator: Roche Pharma AG
• Information provided by (Responsible Party): LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital

Study Description

Brief Summary:

A Multi-center, III Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer

Condition or disease
Breast Cancer; Capecitabine; Triple Negative Breast Cancer

Detailed Description:

Capecitabine comes as a tablet to take by mouth. It is usually taken twice a day (in the morning and in the evening) for 2 weeks, followed by a 1 week break before repeating the next dosage cycle. In this study, capecitabine will be prescribed as dosage of 900mg/m2, and maintain for a whole year after the standard treatment in operable triple negative breast cancer patients. DFS is set as the primary outcome, OS and DDFS are also observed as the secondary outcomes. Statistical analysis are made to see whether this metronomic therapy of capecitabine ( 900mg/m2) will bring benefit to any of the iterms above.

Study Design

• Study Type: Observational
• Estimated Enrollment: 340 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
• Study Start Date: January 2013
• Estimated Primary Completion Date: December 2015
• Estimated Study Completion Date: December 2018

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. PFS（Progression-free survival） [ Time Frame: Progression-free survival：time from the date of randomization until the date of disease progression，assessed up to 3 years ]
   PFS was defined as the time from the date of randomization until the date of disease progression at any site including distant metastasis or second primary tumors or death， assessed up to 3 years

Secondary Outcome Measures :

1. OS [ Time Frame: time from the date of randomization until the date of any death occurred ]
   OS was defined as the time from the date of randomization until the date of any death occurred
2. DDFS [ Time Frame: time from the date of randomization until the date of any disease occurred ]

Biospecimen Retention:   Samples With DNA

10 ml blood sample is taken before randomization

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

Breast cancer patients of vascular endocrine surgery department in Xijing Hospital

Criteria

Inclusion Criteria:

• Female;
• aged 18 - 70 years old;
• Histological confirmed with unilateral invasive carcinoma (all pathological types are applicable);
• Newly diagnosed conditions allowing direct surgery without any absolute contraindication for surgery;
• No mass or microscopic tumor residue after surgery resection;
• Initiate adjuvant chemotherapy within 30 days after surgery;
• Axillary lymph node positive (including the sentinel lymph node positive and lymph node positive after axillary dissection), for example, axillary lymph node negative requires that primary tumor size must be greater than 1cm;
• Definite reports on ER/PR(progesterone receptor)/Her2 receptor showing all ER/PR/Her2 negative (specific definitions: immunohistochemical detection of ER <10% tumor cells is defined as ER negative, PR <10% positive tumor cells is defined as PR-negative, Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no amplification) is defined as Her2 negative);
• No relevant clinical or imaging evidence of metastasis showing in the preoperative examination (M0);
• Without peripheral neuropathy;
• ECOG performance score is 0 or 1;
• Postoperative recovery was good and an interval of at least one week since the surgery is necessary;
• White blood cell count> 4 × 10^9/l, neutrophil count> 2 × 10^9/l, platelet count> 100 × 10^9/l and hemoglobin 9g/dl);
• ASAT and ALAT <1.5 folds of the upper limit of normal values, alkaline phosphatase <2.5 folds of the upper limit of normal values, total bilirubin <1.5 folds of the upper limit of normal values;
• Serum creatinine <1.5 folds of the upper limit of normal value;
• Women at childbearing age should take contraception measures during treatment;
• Cardiac function: echocardiographic examination showed LEVF> 50%;
• Informed consent form signed.

Exclusion Criteria:

• Bilateral breast cancer or carcinoma in situ (DCIS / LCIS);
• Metastasis at any location;
• Any tumor > T4a (UICC1987) (accompanied by skin involvement, lump adhesion and fixation, inflammatory breast cancer);
• Any of ER, PR or Her-2 is positive;
• Contralateral breast clinically or radiologically suspected to be malignant but not confirmed which needs a biopsy;
• Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone therapy;
• Previously suffering from malignant tumors (except for basal cell carcinoma and cervical carcinoma in situ), including contralateral breast cancer;
• Already enrolled into other clinical trials;
• Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this study LEVF <50% (echocardiography);
• Suffering from severe cardiovascular and cerebrovascular diseases within six months before the randomization (such as: unstable angina, chronic heart failure, uncontrollable high blood pressure > 150/90mmHg, myocardial infarction or brain vascular accident);
• Known allergic to taxane and anthracycline agents;
• Women at childbearing age refuse to take contraception measures during the treatment and 8 weeks after completion of treatment;
• Pregnant and breast-feeding women;
• Pregnancy test showed positive results before drug administration after enrolling in to the study; With mental illness and cognitive impairment, unable to understand trial protocol and side effects and complete trial protocol and follow-ups (systematic evaluation is required before recruiting into this study);
• Without personal freedom and independent civil capacity.

Contacts and Locations

Contacts

Contact: Chen Cong, Master; +86-13649294730; congcongfeiyang@126.com

Locations

China, Shaanxi

Xijing Hospital ，Fourth Military Medical University; Recruiting

Xi'an, Shaanxi, China, 710032

Contact: Nanlin Li, Doctor +86-137-0911-3279 nanlin-74@163.com

Contact: Chen Cong, Master +86-136-4929-4730 congcongfeiyang@126.com

Sponsors and Collaborators

Xijing Hospital

Roche Pharma AG

Investigators

• Principal Investigator: Nanlin Li, Doctor; Air Force Military Medical University, China

More Information

• Responsible Party: LiNanlin,Ph.D, Chief Physician,Clinical Professor, The department of Vascular endocrine surgery, Xijing Hospital
• ClinicalTrials.gov Identifier: NCT02012634
• Other Study ID Numbers: TPYS-01
• First Posted: December 16, 2013
• Last Update Posted: November 13, 2014
• Last Verified: November 2014

Keywords provided by LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital:

Breast Cancer; Capecitabine; Triple Negative Breast CancerTNBC（TNBC）

Additional relevant MeSH terms:

Breast Neoplasms; Triple Negative Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases